Telix Pharmaceuticals guides FY 2026 revenue $950M–$970M and R&D $230M–$270M
Telix Pharmaceuticals guides FY 2026 revenue to $950M–$970M and expects total income above $1B, while reaffirming R&D expenditure of $230M–$270M, supported by other income from Regeneron.
Guidance FY 2026 revenue and other income are expected to be in excess of US$1 billion, with revenue progressing in line with the upper end of FY 2026 guidance of US$950 million to US$970 million and US$40 million of other income received from Regeneron.
Telix reaffirms R&D expenditure guidance of US$230 million to US$270 million, enabled by the Company’s strong commercial performance and initial payment of US$40 million received from Regeneron.